Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Coccidioidomycosis Clear all
Completed Not applicable Interventional

Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients

NCT00002062
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Spiramycin
Drug
Lead sponsor
Rhone-Poulenc Rorer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Horsham, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 11:24 AM EDT
Recruiting Phase 4 Interventional

Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

NCT00004317
View directory record Official record
Conditions
Toxoplasmosis
Interventions
Leucovorin calcium, Pyrimethamine, Spiramycin, Sulfadiazine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2009 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Efficacy and Safety of ABO809 in Healthy Participants

NCT05036668
View directory record Official record
Conditions
Cryptosporidium Infection, Cryptosporidiosis
Interventions
Cryptosporidium parvum oocysts (ABO809)
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 29, 2026, 11:24 AM EDT
Withdrawn Phase 2 Interventional

SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole

NCT04809649
View directory record Official record
Conditions
Coccidioidomycosis, Valley Fever
Interventions
SUBA-itraconazole
Drug
Lead sponsor
George R Thompson
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 1 Interventional

A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients

NCT00002248
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Cryptosporidium Immune Whey Protein Concentrate (Bovine)
Drug
Lead sponsor
Univax Biologics Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional

A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium

NCT00001081
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Nitazoxanide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 29, 2026, 11:24 AM EDT
Not listed Not applicable Interventional

A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis

NCT00002158
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Nitazoxanide
Drug
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
3 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2007 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional

Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients

NCT00000643
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
24
States / cities
Palo Alto, California • Torrance, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Not applicable Interventional

A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS

NCT00000674
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine, Leucovorin calcium, Clindamycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Not applicable Interventional

A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common

NCT00002325
View directory record Official record
Conditions
Mycoses, HIV Infections, Coccidioidomycosis
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Phoenix, Arizona • Tucson, Arizona • Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

NCT00869713
View directory record Official record
Conditions
Rift Valley Fever
Interventions
Inactivated, Dried (TSI-GSD 200), RVF Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 29, 2026, 11:24 AM EDT
Recruiting Phase 2 Interventional

Olorofim in Early Coccidioidal Meningitis

NCT07385638
View directory record Official record
Conditions
Coccidioidal Meningitis
Interventions
olorofim
Drug
Lead sponsor
Fariba Donovan
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Not applicable Interventional

Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

NCT00002064
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine, Clindamycin
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

NCT00415051
View directory record Official record
Conditions
Rift Valley Fever
Interventions
RVF MP-12
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 29, 2026, 11:24 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011

NCT06925919
View directory record Official record
Conditions
Rift Valley Fever
Interventions
IDB-011 dose level 1, IDB-011 dose level 2, IDB-011 dose level 3, IDB-011 dose level 4, IDB-011 dose level 5, Placebo
Drug · Other
Lead sponsor
IDBiologics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

NCT02663674
View directory record Official record
Conditions
Coccidioidomycosis
Interventions
Fluconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Not applicable Interventional

A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine

NCT00001994
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Atovaquone
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 11:24 AM EDT
Not yet recruiting Phase 2 Interventional

Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi

NCT07804368
View directory record Official record
Conditions
Coccidioidomycosis, Blastomycosis, Histoplasmosis, Dimorphic Fungal Infection, Endemic Mycoses
Interventions
Oteseconazole
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Phoenix, Arizona • Tempe, Arizona • Davis, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Not applicable Interventional

Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis

NCT00002010
View directory record Official record
Conditions
Meningitis, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Tucson, Arizona • San Diego, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 1 Interventional

A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS

NCT00000966
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Azithromycin, Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Worcester, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Not applicable Interventional

The Effectiveness of Cow's Milk Immune Globulin in the Treatment of AIDS-Related Diarrhea

NCT00002264
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Cryptosporidium Immune Whey Protein Concentrate (Bovine)
Drug
Lead sponsor
Stolle Milk Biologic International
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Not applicable Interventional

Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study

NCT00002082
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Oakland, California • San Diego, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 11:24 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults

NCT07249463
View directory record Official record
Conditions
Cryptosporidiosis
Interventions
Cryptosporidium parvum oocysts (ABO809), EDI048, Placebo
Biological · Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Terminated Not applicable Interventional

Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment

NCT03618992
View directory record Official record
Conditions
Valley Fever, Coccidioidomycosis
Interventions
Cholesterol-containing moisturizers
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 29, 2026, 11:24 AM EDT